In experimental autoimmune encephalomyelitis as an animal model of MS, deficiency of Nfatc1 and/or Nfatc2 ameliorated demyelination suggesting that blocking NFAT activity might be a treatment strategy in MS37. Here, NFATC1 is linked to experimental autoimmune encephalomyelitis.